TWEAK, a multifunctional cytokine in kidney injury

Kidney International

Volumn 80, Issue 7, 2011, Pages 708-718

  Sanz, Ana Belen ^a   Sanchez Nĩo, Maria D ^a   Ortiz, Alberto ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

acute kidney injury; inflammation; intrinsic renal cells; lupus nephritis; TNF

Indexed keywords

FN14 RECEPTOR; RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

APOPTOSIS; CELL DIFFERENTIATION; CELL HYPERPLASIA; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CYTOKINE RELEASE; DISEASE MODEL; HUMAN; HYPERLIPIDEMIA; KIDNEY CELL; KIDNEY INJURY; KIDNEY TUBULE CELL; LEUKOCYTE; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHRECTOMY; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; UPREGULATION;

EID: 80052858870     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.180     Document Type: Review

References (116)

1. Chicheportiche Y, Bourdon PR, Xu H et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997; 272: 32401-32410. (Pubitemid 28011923)
2. Foster D, Parrish-Novak J, Fox B et al. Cytokine-receptor pairing: accelerating discovery of cytokine function. Nat Rev Drug Discov 2004; 3: 160-170. (Pubitemid 38239777)
3. Grewal IS. Overview of TNF superfamily: a chest full of potential therapeutic targets. Adv Exp Med Biol 2009; 647: 1-7.
4. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501. (Pubitemid 32201945)
5. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002; 27: 19-26. (Pubitemid 34131621)
6. Brown SA, Ghosh A, Winkles JA. Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem 2010; 285: 17432-17441.
7. Nakayama M, Kayagaki N, Yamaguchi N et al. Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med 2000; 192: 1373-1380.
8. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; 7: 411-425. (Pubitemid 351619113)
9. Marsters SA, Sheridan JP, Pitti RM et al. Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol 1998; 8: 525-528. (Pubitemid 28203072)
10. De Kooten A, Vermeulen L, Vialard J et al. Involvement of GSK-3beta in TWEAK-mediated NF-kappaB activation. FEBS Lett 2004; 566: 60-64. (Pubitemid 38625933)
11. Baxter FO, Came PJ, Abell K et al. IKKbeta/2 induces TWEAK and apoptosis in mammary epithelial cells. Development 2006; 133: 3485-3494. (Pubitemid 44501850)
12. Roos C, Wicovsky A, Muller N et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol 2010; 185: 1593-1605.
13. Kaptein A, Jansen M, Dilaver G et al. Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMP (DR3). FEBS Lett 2000; 485: 135-141.
14. Kaplan MJ, Lewis EE, Shelden EA et al. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 2002; 169: 6020-6029. (Pubitemid 35291710)
15. Wiley SR, Cassiano L, Lofton T et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001; 15: 837-846. (Pubitemid 34008510)
16. Feng SL, Guo Y, Factor VM et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 2000; 156: 1253-1261. (Pubitemid 30660004)
17. Meighan-Mantha RL, Hsu DK, Guo Y et al. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 1999; 274: 33166-33176. (Pubitemid 129535361)
18. Brown SA, Richards CM, Hanscom HN et al. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J 2003; 371: 395-403. (Pubitemid 36547622)
19. He F, Dang W, Saito K et al. Solution structure of the cysteine-rich domain in Fn14, a member of the tumor necrosis factor receptor superfamily. Protein Sci 2009; 18: 650-656.
20. Polek TC, Talpaz M, Darnay BG et al. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem 2003; 278: 32317-32323. (Pubitemid 37048427)
21. Bover LC, Cardo-Vila M, Kuniyasu A et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 2007; 178: 8183-8194. (Pubitemid 46898091)
22. Moreno JA, Munoz-Garcia B, Martin-Ventura JL et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 2009; 207: 103-110.
23. Jakubowski A, Ambrose C, Parr M et al. TWEAK induces liver progenitor cell proliferation. J Clin Invest 2005; 115: 2330-2340. (Pubitemid 41266195)
24. Lynch CN, Wang YC, Lund JK et al. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999; 274: 8455-8459. (Pubitemid 29164634)
25. Maecker H, Varfolomeev E, Kischkel F et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell 2005; 123: 931-944. (Pubitemid 41721037)
26. Nakayama M, Harada N, Okumura K et al. Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun 2003; 306: 819-825. (Pubitemid 36776204)
27. Naumann M, Nieters A, Hatada EN et al. NF-kappa B precursor p100 inhibits nuclear translocation and DNA binding of NF-kappa B/rel-factors. Oncogene 1993; 8: 2275-2281. (Pubitemid 23226963)
28. Tran NL, McDonough WS, Savitch BA et al. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005; 280: 3483-3492. (Pubitemid 40223813)
29. Mittal A, Bhatnagar S, Kumar A et al. The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J Cell Biol 2010; 188: 833-849.
30. Wang D, Fung JN, Tuo Y et al. TWEAK/Fn14 promotes apoptosis of human endometrial cancer cells via caspase pathway. Cancer Lett 2010; 294: 91-100.
31. Novoyatleva T, Diehl F, van Amerongen MJ et al. TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovasc Res 2010; 85: 681-690.
32. Tiller G, Fischer-Posovszky P, Laumen H et al. Effects of TWEAK (TNF superfamily member 12) on differentiation, metabolism, and secretory function of human primary preadipocytes and adipocytes. Endocrinology 2009; 150: 5373-5383.
33. Justo P, Sanz AB, Sanchez-Nino MD et al. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int 2006; 70: 1750-1758. (Pubitemid 44684806)
34. Tirnitz-Parker JE, Viebahn CS, Jakubowski A et al. Tumor necrosis factorlike weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology 2010; 52: 291-302.
35. Desplat-Jego S, Creidy R, Varriale S et al. Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol 2005; 117: 15-23. (Pubitemid 41725465)
36. Dohi T, Borodovsky A, Wu P et al. TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. Gastroenterology 2009; 136: 912-923.
37. Munoz-Garcia B, Moreno JA, Lopez-Franco O et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 2009; 29: 2061-2068.
38. Munoz-Garcia B, Madrigal-Matute J, Moreno JA et al. TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovasc Res 2011; 89: 225-233.
39. Haile WB, Echeverry R, Wu J et al. The interaction between tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 promotes the recruitment of neutrophils into the ischemic brain. J Cereb Blood Flow Metab 2010; 30: 1147-1156.
40. Burkly LC, Michaelson JS, Hahm K et al. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007; 40: 1-16. (Pubitemid 350088500)
41. Girgenrath M, Weng S, Kostek CA et al. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J 2006; 25: 5826-5839. (Pubitemid 44967766)
42. Vendrell J, Maymo-Masip E, Tinahones F et al. Tumor necrosis-like weak inducer of apoptosis as a proinflammatory cytokine in human adipocyte cells: up-regulation in severe obesity is mediated by inflammation but not hypoxia. J Clin Endocrinol Metab 2010; 95: 2983-2992.
43. Mustonen E, Sakkinen H, Tokola H et al. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14 during cardiac remodelling in rats. Acta Physiol (Oxf) 2010; 199: 11-22.
44. Hotta K, Sho M, Yamato I et al. Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int 2011; 79: 179-188.
45. Sanz AB, Sanchez-Nino MD, Izquierdo MC et al. Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. J Cell Mol Med 2009; 13: 3329-3342.
46. Kim SH, Kang YJ, Kim WJ et al. TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 2004; 68: 396-399.
47. Molano A, Lakhani P, Aran A et al. TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. Immunol Lett 2009; 125: 119-128.
48. Gao HX, Campbell SR, Burkly LC et al. TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine 2009; 46: 24-35.
49. Munoz-Garcia B, Martin-Ventura JL, Martinez E et al. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke 2006; 37: 2044-2053. (Pubitemid 44309902)
50. Donohue PJ, Richards CM, Brown SA et al. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003; 23: 594-600. (Pubitemid 36438071)
51. Chorianopoulos E, Heger T, Lutz M et al. FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. Basic Res Cardiol 2010; 105: 301-313.
52. Campbell S, Burkly LC, Gao HX et al. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol 2006; 176: 1889-1898. (Pubitemid 43134334)
53. van KC, Daha MR, van Es LA. Tubular epithelial cells: a critical cell type in the regulation of renal inflammatory processes. Exp Nephrol 1999; 7: 429-437. (Pubitemid 29517353)
54. de Haij S, Daha MR, van KC. Mechanism of steroid action in renal epithelial cells. Kidney Int 2004; 65: 1577-1588. (Pubitemid 38591004)
55. Sanz AB, Sanchez-Nino MD, Ramos AM et al. NF-kappaB in renal inflammation. J Am Soc Nephrol 2010; 21: 1254-1262.
56. Sanz AB, Justo P, Sanchez-Nino MD et al. The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 2008; 19: 695-703.
57. Sanz AB, Sanchez-Nino MD, Izquierdo MC et al. TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS One 2010; 5: e8955.
58. Saitoh T, Nakayama M, Nakano H et al. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 2003; 278: 36005-36012. (Pubitemid 37139919)
59. Banas B, Wornle M, Berger T et al. Roles of SLC/CCL21 and CCR7 in human kidney for mesangial proliferation, migration, apoptosis, and tissue homeostasis. J Immunol 2002; 168: 4301-4307. (Pubitemid 34441329)
60. Ando T, Ichikawa J, Wako M et al. TWEAK/Fn14 interaction regulates RANTES production, BMP-2-induced differentiation, and RANKL expression in mouse osteoblastic MC3T3-E1 cells. Arthritis Res Ther 2006; 8: R146.
61. Li H, Mittal A, Paul PK et al. Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential role of MMP-9 in myopathy. J Biol Chem 2009; 284: 4439-4450.
62. Solez K, Morel-Maroger L, Sraer JD. The morphology of 'acute tubular necrosis' in man: analysis of 57 renal biopsies and a comparison with the glycerol model. Medicine (Baltimore) 1979; 58: 362-376. (Pubitemid 10234879)
63. Ortiz A, Lorz C, Catalan MP et al. Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure. Kidney Int 2000; 57: 969-981. (Pubitemid 30434787)
64. Lorz C, Benito-Martin A, Boucherot A et al. The death ligand TRAIL in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 904-914.
65. Ortiz A, Bustos C, Alonso J et al. Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. Adv Nephrol Necker Hosp 1995; 24: 53-77.
66. Ortiz A, Lorz C, Egido J. New kids in the block: the role of FasL and Fas in kidney damage. J Nephrol 1999; 12: 150-158. (Pubitemid 29370822)
67. Alderson MR, Armitage RJ, Maraskovsky E et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993; 178: 2231-2235. (Pubitemid 23344883)
68. Potrovita I, Zhang W, Burkly L et al. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci 2004; 24: 8237-8244. (Pubitemid 39280803)
69. Michaelson JS, Burkly LC. Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway. Results Probl Cell Differ 2009; 49: 145-160.
70. Goes N, Urmson J, Vincent D et al. Acute renal injury in the interferongamma gene knockout mouse: effect on cytokine gene expression. Transplantation 1995; 60: 1560-1564. (Pubitemid 26012693)
71. Nakayama M, Ishidoh K, Kojima Y et al. Fibroblast growth factorinducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol 2003; 170: 341-348. (Pubitemid 36026158)
72. Vince JE, Chau D, Callus B et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 2008; 182: 171-184. (Pubitemid 352008630)
73. Cauwels A, Janssen B, Waeytens A et al. Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2. Nat Immunol 2003; 4: 387-393. (Pubitemid 36432323)
74. Ortiz A, Justo P, Catalan MP et al. Apoptotic cell death in renal injury: the rationale for intervention. Curr Drug Targets Immune Endocr Metabol Disord 2002; 2: 181-192.
75. Webber EM, Bruix J, Pierce RH et al. Tumor necrosis factor primes hepatocytes for DNA replication in the rat. Hepatology 1998; 28: 1226-1234. (Pubitemid 28493831)
76. Yamada Y, Webber EM, Kirillova I et al. Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not type 2 receptor. Hepatology 1998; 28: 959-970. (Pubitemid 28450256)
77. Desplat-Jego S, Varriale S, Creidy R et al. TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol 2002; 133: 116-123. (Pubitemid 35346733)
78. Vincent C, Findlay DM, Welldon KJ et al. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 2009; 24: 1434-1449.
79. Scholzke MN, Rottinger A, Murikinati S et al. TWEAK regulates proliferation and differentiation of adult neural progenitor cells. Mol Cell Neurosci 2011; 46: 325-332.
80. Justo P, Sanz A, Lorz C et al. Expression of Smac/Diablo in tubular epithelial cells and during acute renal failure. Kidney Int Suppl 2003; 86: S52-S56. (Pubitemid 37159628)
81. Dionne S, Levy E, Levesque D et al. PPARgamma ligand 15-deoxy-delta 12,14-prostaglandin J2 sensitizes human colon carcinoma cells to TWEAK-induced apoptosis. Anticancer Res 2010; 30: 157-166.
82. Kataria NG, Bartold PM, Dharmapatni AA et al. Expression of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor, fibroblast growth factor-inducible 14 protein (Fn14), in healthy tissues and in tissues affected by periodontitis. J Periodontal Res 2010; 45: 564-573.
83. Inta I, Frauenknecht K, Dorr H et al. Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke. J Neurol Sci 2008; 275: 117-120.
84. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B et al. TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. Front Biosci 2007; 12: 3648-3655.
85. Chicheportiche Y, Fossati-Jimack L, Moll S et al. Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem Biophys Res Commun 2000; 279: 162-165.
86. Schwartz N, Su L, Burkly LC et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006; 27: 242-250. (Pubitemid 46206104)
87. Liu ZC, Zhou QL, Li XZ et al. Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Cytokine 2011; 53: 295-300.
88. Zhao Z, Burkly LC, Campbell S et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graftversus-host model of systemic lupus erythematosus. J Immunol 2007; 179: 7949-7958.
89. Monrad SU, Killen PD, Anderson MR et al. The role of aldosterone blockade in murine lupus nephritis. Arthritis Res Ther 2008; 10: R5.
90. Cleary CM, Moreno JA, Fernandez B et al. Glomerular haematuria, renal interstitial haemorrhage and acute kidney injury. Nephrol Dial Transplant 2010; 25: 4103-4106.
91. Metz-Kurschel U, Kurschel E, Wagner K et al. Folate nephropathy occurring during cytotoxic chemotherapy with high-dose folinic acid and 5-fluorouracil. Ren Fail 1990; 12: 93-97. (Pubitemid 20345930)
92. Ortega A, Ramila D, Ardura JA et al. Role of parathyroid hormone-related protein in tubulointerstitial apoptosis and fibrosis after folic acidinduced nephrotoxicity. J Am Soc Nephrol 2006; 17: 1594-1603. (Pubitemid 43794662)
93. de Haij S, Woltman AM, Bakker AC et al. Production of inflammatory mediators by renal epithelial cells is insensitive to glucocorticoids. Br J Pharmacol 2002; 137: 197-204.
94. Nakashima Y, Plump AS, Raines EW et al. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994; 14: 133-140.
95. Buzello M, Haas CS, Hauptmann F et al. No aggravation of renal injury in apolipoprotein E knockout mice (ApoE(f/2)) after subtotal nephrectomy. Nephrol Dial Transplant 2004; 19: 566-573. (Pubitemid 38263114)
96. Bruneval P, Bariety J, Belair MF et al. Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apoE null mice. Nephrol Dial Transplant 2002; 17: 2099-2107. (Pubitemid 35446664)
97. Wen M, Segerer S, Dantas M et al. Renal injury in apolipoprotein E-deficient mice. Lab Invest 2002; 82: 999-1006.
98. Sun J, Langer WJ, Devish K et al. Compensatory kidney growth in estrogen receptor-alpha null mice. Am J Physiol Renal Physiol 2006; 290: F319-F323. (Pubitemid 43724987)
99. Flyvbjerg A, Bennett WF, Rasch R et al. Compensatory renal growth in uninephrectomized adult mice is growth hormone dependent. Kidney Int 1999; 56: 2048-2054. (Pubitemid 30004733)
100. Tanabe K, Bonilla I, Winkles JA et al. Fibroblast growth factor-inducible-14 is induced in axotomized neurons and promotes neurite outgrowth. J Neurosci 2003; 23: 9675-9686. (Pubitemid 37352067)
101. Kamata K, Kamijo S, Nakajima A et al. Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J Immunol 2006; 177: 6433-6439. (Pubitemid 44628862)
102. Moreno JA, Dejouvencel T, Labreuche J et al. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol 2010; 30: 1253-1262.
103. Jelic-Ivanovic Z, Bujisic N, Spasic S et al. Circulating sTWEAK improves the prediction of coronary artery disease. Clin Biochem 2009; 42: 1381-1386.
104. Chorianopoulos E, Rosenberg M, Zugck C et al. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur J Heart Fail 2009; 11: 1050-1056.
105. Richter B, Rychli K, Hohensinner PJ et al. Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis 2010; 213: 545-548.
106. Martin-Ventura JL, Lindholt JS, Moreno JA et al. Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis 2011; 214: 486-489.
107. Carrero JJ, Ortiz A, Qureshi AR et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 110-118.
108. Yilmaz MI, Carrero JJ, Ortiz A et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1716-1723.
109. Kralisch S, Ziegelmeier M, Bachmann A et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008; 199: 440-444. (Pubitemid 352020411)
110. Yilmaz MI, Carrero JJ, Martin-Ventura JL et al. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 2010; 5: 1174-1181.
111. Nagasawa M, Yi Z, Imashuku S et al. Soluble TWEAK is markedly elevated in hemophagocytic lymphohistiocytosis. Am J Hematol 2008; 83: 222-225. (Pubitemid 351303947)
112. Williams SA, Martin SK, Vincent C et al. Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patients. Br J Haematol 2010; 150: 373-376.
113. ElGendi SS, El-Sherif WT. Anti-C1q antibodies, sCD40L, TWEAK and CD4/CD8 ratio in systemic lupus erythematosus and their relations to disease activity and renal involvement. Egypt J Immunol 2009; 16: 135-148.
114. Chorianopoulos E, Jarr K, Steen H et al. Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis 2010; 211: 322-326.
115. Cross J, Jayne D. Diagnosis and treatment of kidney disease. Best Pract Res Clin Rheumatol 2005; 19: 785-798. (Pubitemid 41258583)
116. Schwartz N, Rubinstein T, Burkly LC et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009; 11: R143.